The multi-epitope polypeptide approach in HIV-1 vaccine development.
The application of a preventive HIV vaccine is the only hope for most developing countries to halt the AIDS pandemic. A project aimed to develop a preventive AIDS vaccine is being carried out since 1992 by three Cuban research institutions: Centro de Ingeniería Genética y Biotecnologia de La Habana, Instituto de Medicina Tropical 'Pedro Kouri' and Laboratorio de Investigaciones de SIDA de La Habana. The project includes two main strategies: (a) generation of recombinant multi-epitope polypeptides (MEPs) bearing several copies of the V3 loop from different HIV-1 isolates; and (b) development of immunogens capable of inducing a cytotoxic T cell response (CTL) specific for human immunodeficiency virus type 1 (HIV-1) antigens. This article summarizes the work in the first of these strategies. Based on the sequence of the V3 loop of HIV-1 we constructed a series of MEPs and evaluated their immunogenicity in mice, rabbits and macaques. The MEP TAB9, containing six V3 epitopes from isolates LR10, JY1, RF, MN, BRVA and IIIB, was selected together with the oil adjuvant Montanide ISA720 (SEPPIC, France) to perform a Phase I clinical trial in HIV seronegative Cuban volunteers. The trial was double blinded, randomized, and fulfilled all ethical and regulatory requirements. All TAB9 vaccinated volunteers developed a strong immune response and neutralizing antibodies were observed in the 50% of the subjects. However the second and third inoculations of the vaccine were not well tolerated because transient severe local reactions appeared in some individuals. A new formulation of TAB9 is currently in pre-clinical studies and is expected to enter clinical trials in 1999.
Cano
C A
CA
Jefe Departamento SIDA, Centro de Ingeniería Genética y Biotecnologia, La Habana, Playa, Cuba. carlos.duarte@cigb.edu.cu
D016915:AIDS Vaccines / Q000009:adverse effects / Q000276:immunology*; D000276:Adjuvants, Immunologic; D000818:Animals; D003462:Cuba; D003602:Cytotoxicity, Immunologic; D004311:Double-Blind Method; D000939:Epitopes / Q000276:immunology*; D005813:Genes, Synthetic; D015488:HIV Antigens / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D000882:Haplorhini; D006801:Humans; D007115:Immunization Schedule; D008252:Macaca fascicularis; D008353:Mannitol / Q000031:analogs & derivatives; D051379:Mice; D009829:Oleic Acids; D010446:Peptide Fragments / Q000276:immunology*; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology*
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000939:Epitopes; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D009829:Oleic Acids; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; C001681:mannide monooleate; D008353:Mannitol